Siegfried, a worldwide leading CDMO, produces active pharmaceutical ingredients (APIs), intermediates and finished products from a single source. Our core competence is process development and the integration of complementary chemical and pharmaceutical capabilities in a single business model.
“We have coped well with the challenges posed by COVID-19 and have kept our company on track.”
The change compared to last year is +2.2% in local currencies (–1.5% in CHF).
The change compared to last year is –12.4%.
Report
“In 2019, Siegfried attached great importance to effective networking among its production sites. Consequently, management has initiated numerous internal projects, which will allow us to increasingly act as a global team across all of our sites.”
Dr. Andreas Casutt
Chairman of the Board of Directors
Dr. Wolfgang Wienand
Chief Executive Officer
Dear Shareholders
The Siegfried Group looks back on a successful 2019 financial year in which it achieved its goal of profitable growth. Sales amounted to 833.5 million Swiss francs which, compared to the previous year, represents growth of 6.9 percent in local currencies, or 4.9 percent in Swiss francs. Core EBITDA (earnings before interest, taxes and amortization) grew by 11.3 percent to 140.7 million Swiss francs. This corresponds to a core EBITDA margin of 16.9 percent, 1 percent above the previous year’s value (2018: 15.9 percent). Core EBITDA thus again grew faster than sales. Core net profit of 65.7 million Swiss francs is reported clearly above that of the previous year (55.4 million), representing an increase of 18.5 percent.
Financials
Change in net sales compared to the previous year (in LC): Sales grew by 6.9%.
The change compared to the previous year was +11.3%.
Financial Commentary on the 2019 Report
Positive growth and higher margins
Siegfried sales reported for 2019 at 833.5 Mio Swiss Francs demonstrate continued strong growth. This is in spite of adverse headwinds from a foreign exchange rate movement in the Euro. Sales growth in local currencies is 6.9% and 4.9% in Swiss Francs; Gross Profit 172.7 Mio Swiss Francs has grown ahead of the top line sales by 10.3%.